nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—thyroid cancer—head and neck cancer	0.456	1	CtDrD
Vandetanib—VEGFA—head and neck cancer	0.144	0.542	CbGaD
Vandetanib—EGFR—head and neck cancer	0.122	0.458	CbGaD
Vandetanib—EGFR—Docetaxel—head and neck cancer	0.0621	0.464	CbGbCtD
Vandetanib—ABCC1—Vinblastine—head and neck cancer	0.0186	0.139	CbGbCtD
Vandetanib—ABCC1—Docetaxel—head and neck cancer	0.0153	0.114	CbGbCtD
Vandetanib—ABCG2—Fluorouracil—head and neck cancer	0.0134	0.1	CbGbCtD
Vandetanib—ABCG2—Docetaxel—head and neck cancer	0.0103	0.0766	CbGbCtD
Vandetanib—ALB—Fluorouracil—head and neck cancer	0.00926	0.0691	CbGbCtD
Vandetanib—CYP3A4—Vinblastine—head and neck cancer	0.00269	0.0201	CbGbCtD
Vandetanib—CYP3A4—Docetaxel—head and neck cancer	0.00222	0.0165	CbGbCtD
Vandetanib—LTK—tongue—head and neck cancer	0.00116	0.0286	CbGeAlD
Vandetanib—RET—parathyroid gland—head and neck cancer	0.00111	0.0275	CbGeAlD
Vandetanib—PTK6—hair follicle—head and neck cancer	0.000951	0.0235	CbGeAlD
Vandetanib—LTK—mouth—head and neck cancer	0.000778	0.0193	CbGeAlD
Vandetanib—Afatinib—EGFR—head and neck cancer	0.000755	0.308	CrCbGaD
Vandetanib—ORM1—saliva—head and neck cancer	0.000629	0.0156	CbGeAlD
Vandetanib—Mucosal inflammation—Hydroxyurea—head and neck cancer	0.000619	0.0215	CcSEcCtD
Vandetanib—Platelet count decreased—Hydroxyurea—head and neck cancer	0.000576	0.02	CcSEcCtD
Vandetanib—Dysaesthesia—Fluorouracil—head and neck cancer	0.00057	0.0198	CcSEcCtD
Vandetanib—Pericarditis—Fluorouracil—head and neck cancer	0.00057	0.0198	CcSEcCtD
Vandetanib—ERBB3—exocrine gland—head and neck cancer	0.000567	0.014	CbGeAlD
Vandetanib—Photopsia—Docetaxel—head and neck cancer	0.00056	0.0194	CcSEcCtD
Vandetanib—ERBB3—hair follicle—head and neck cancer	0.000541	0.0134	CbGeAlD
Vandetanib—Hypomagnesaemia—Hydroxyurea—head and neck cancer	0.00054	0.0187	CcSEcCtD
Vandetanib—Erlotinib—EGFR—head and neck cancer	0.000533	0.218	CrCbGaD
Vandetanib—Ileus—Vinblastine—head and neck cancer	0.000531	0.0184	CcSEcCtD
Vandetanib—MKNK1—hair follicle—head and neck cancer	0.000508	0.0126	CbGeAlD
Vandetanib—PTK6—saliva-secreting gland—head and neck cancer	0.000498	0.0123	CbGeAlD
Vandetanib—Sudden death—Fluorouracil—head and neck cancer	0.000482	0.0167	CcSEcCtD
Vandetanib—MAP4K5—hair follicle—head and neck cancer	0.000457	0.0113	CbGeAlD
Vandetanib—Balance disorder—Fluorouracil—head and neck cancer	0.000451	0.0156	CcSEcCtD
Vandetanib—Skin ulcer—Hydroxyurea—head and neck cancer	0.00044	0.0153	CcSEcCtD
Vandetanib—ERBB3—mouth—head and neck cancer	0.000424	0.0105	CbGeAlD
Vandetanib—YES1—hair follicle—head and neck cancer	0.000422	0.0104	CbGeAlD
Vandetanib—Cellulitis—Vinblastine—head and neck cancer	0.000413	0.0143	CcSEcCtD
Vandetanib—Dysaesthesia—Docetaxel—head and neck cancer	0.000412	0.0143	CcSEcCtD
Vandetanib—PTK6—trachea—head and neck cancer	0.000384	0.0095	CbGeAlD
Vandetanib—Nail disorder—Fluorouracil—head and neck cancer	0.00038	0.0132	CcSEcCtD
Vandetanib—Creatinine increased—Hydroxyurea—head and neck cancer	0.00036	0.0125	CcSEcCtD
Vandetanib—TYRO3—connective tissue—head and neck cancer	0.000354	0.00875	CbGeAlD
Vandetanib—BLK—lymphoid tissue—head and neck cancer	0.000353	0.00873	CbGeAlD
Vandetanib—LYN—connective tissue—head and neck cancer	0.000352	0.00871	CbGeAlD
Vandetanib—Neoplasm—Vinblastine—head and neck cancer	0.00034	0.0118	CcSEcCtD
Vandetanib—RET—neck—head and neck cancer	0.000336	0.00833	CbGeAlD
Vandetanib—Gefitinib—EGFR—head and neck cancer	0.000334	0.136	CrCbGaD
Vandetanib—BMPR1B—epithelium—head and neck cancer	0.000329	0.00814	CbGeAlD
Vandetanib—Bosutinib—EGFR—head and neck cancer	0.000329	0.134	CrCbGaD
Vandetanib—Mucosal inflammation—Docetaxel—head and neck cancer	0.000322	0.0111	CcSEcCtD
Vandetanib—Neoplasm—Hydroxyurea—head and neck cancer	0.00031	0.0107	CcSEcCtD
Vandetanib—RIPK2—parotid gland—head and neck cancer	0.000309	0.00764	CbGeAlD
Vandetanib—FMO1—parotid gland—head and neck cancer	0.000306	0.00758	CbGeAlD
Vandetanib—Erlotinib—CYP1A1—head and neck cancer	0.000305	0.125	CrCbGaD
Vandetanib—IRAK4—parotid gland—head and neck cancer	0.000301	0.00746	CbGeAlD
Vandetanib—FLT3—connective tissue—head and neck cancer	0.000301	0.00744	CbGeAlD
Vandetanib—RIPK2—saliva-secreting gland—head and neck cancer	0.000296	0.00732	CbGeAlD
Vandetanib—Polyp—Docetaxel—head and neck cancer	0.000293	0.0101	CcSEcCtD
Vandetanib—IRAK4—saliva-secreting gland—head and neck cancer	0.000289	0.00715	CbGeAlD
Vandetanib—ERBB3—saliva-secreting gland—head and neck cancer	0.000283	0.007	CbGeAlD
Vandetanib—LTK—head—head and neck cancer	0.000281	0.00695	CbGeAlD
Vandetanib—PLK4—lymphoid tissue—head and neck cancer	0.000275	0.00681	CbGeAlD
Vandetanib—Nail disorder—Docetaxel—head and neck cancer	0.000275	0.00952	CcSEcCtD
Vandetanib—RIPK2—connective tissue—head and neck cancer	0.000272	0.00672	CbGeAlD
Vandetanib—Cellulitis—Fluorouracil—head and neck cancer	0.000271	0.0094	CcSEcCtD
Vandetanib—EPHA8—head—head and neck cancer	0.000269	0.00667	CbGeAlD
Vandetanib—Cyst—Docetaxel—head and neck cancer	0.000266	0.00923	CcSEcCtD
Vandetanib—FMO3—parotid gland—head and neck cancer	0.000265	0.00655	CbGeAlD
Vandetanib—SLK—parotid gland—head and neck cancer	0.000263	0.0065	CbGeAlD
Vandetanib—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.00026	0.00902	CcSEcCtD
Vandetanib—ERBB3—connective tissue—head and neck cancer	0.00026	0.00644	CbGeAlD
Vandetanib—FLT4—epithelium—head and neck cancer	0.000259	0.00642	CbGeAlD
Vandetanib—Haemoglobin decreased—Docetaxel—head and neck cancer	0.000259	0.00897	CcSEcCtD
Vandetanib—TYRO3—lymphoid tissue—head and neck cancer	0.000259	0.0064	CbGeAlD
Vandetanib—RIPK2—epithelium—head and neck cancer	0.000258	0.00638	CbGeAlD
Vandetanib—LYN—lymphoid tissue—head and neck cancer	0.000257	0.00637	CbGeAlD
Vandetanib—SLK—saliva-secreting gland—head and neck cancer	0.000252	0.00623	CbGeAlD
Vandetanib—Interstitial lung disease—Docetaxel—head and neck cancer	0.000252	0.00872	CcSEcCtD
Vandetanib—Ileus—Docetaxel—head and neck cancer	0.000252	0.00872	CcSEcCtD
Vandetanib—KDR—neck—head and neck cancer	0.00025	0.0062	CbGeAlD
Vandetanib—MAP4K5—parotid gland—head and neck cancer	0.00025	0.00618	CbGeAlD
Vandetanib—ERBB3—epithelium—head and neck cancer	0.000247	0.00611	CbGeAlD
Vandetanib—RET—connective tissue—head and neck cancer	0.000241	0.00597	CbGeAlD
Vandetanib—AXL—connective tissue—head and neck cancer	0.00024	0.00594	CbGeAlD
Vandetanib—MAP4K5—saliva-secreting gland—head and neck cancer	0.000239	0.00592	CbGeAlD
Vandetanib—EPHB6—parotid gland—head and neck cancer	0.000239	0.0059	CbGeAlD
Vandetanib—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.000233	0.00808	CcSEcCtD
Vandetanib—YES1—parotid gland—head and neck cancer	0.000231	0.00571	CbGeAlD
Vandetanib—BMPR1B—thyroid gland—head and neck cancer	0.00023	0.0057	CbGeAlD
Vandetanib—RET—epithelium—head and neck cancer	0.000229	0.00567	CbGeAlD
Vandetanib—EPHB6—saliva-secreting gland—head and neck cancer	0.000228	0.00565	CbGeAlD
Vandetanib—RIPK2—trachea—head and neck cancer	0.000228	0.00564	CbGeAlD
Vandetanib—VEGFA—trachea—head and neck cancer	0.000227	0.00563	CbGeAlD
Vandetanib—FMO1—trachea—head and neck cancer	0.000226	0.0056	CbGeAlD
Vandetanib—FYN—connective tissue—head and neck cancer	0.000225	0.00556	CbGeAlD
Vandetanib—EPHA6—head—head and neck cancer	0.000225	0.00556	CbGeAlD
Vandetanib—IRAK4—trachea—head and neck cancer	0.000223	0.00551	CbGeAlD
Vandetanib—YES1—saliva-secreting gland—head and neck cancer	0.000221	0.00546	CbGeAlD
Vandetanib—FLT3—lymphoid tissue—head and neck cancer	0.00022	0.00544	CbGeAlD
Vandetanib—TEK—connective tissue—head and neck cancer	0.00022	0.00544	CbGeAlD
Vandetanib—ABCC1—hair follicle—head and neck cancer	0.000219	0.00543	CbGeAlD
Vandetanib—ERBB3—trachea—head and neck cancer	0.000218	0.0054	CbGeAlD
Vandetanib—PDGFRB—neck—head and neck cancer	0.000217	0.00537	CbGeAlD
Vandetanib—Sepsis—Fluorouracil—head and neck cancer	0.000214	0.00742	CcSEcCtD
Vandetanib—Pancreatitis—Hydroxyurea—head and neck cancer	0.000211	0.00731	CcSEcCtD
Vandetanib—Depression—Vinblastine—head and neck cancer	0.00021	0.00727	CcSEcCtD
Vandetanib—TEK—epithelium—head and neck cancer	0.000209	0.00516	CbGeAlD
Vandetanib—EPHA5—head—head and neck cancer	0.000208	0.00516	CbGeAlD
Vandetanib—TYRO3—head—head and neck cancer	0.000208	0.00516	CbGeAlD
Vandetanib—LYN—head—head and neck cancer	0.000207	0.00513	CbGeAlD
Vandetanib—BMPR1B—head—head and neck cancer	0.000204	0.00505	CbGeAlD
Vandetanib—MAP3K19—head—head and neck cancer	0.000204	0.00505	CbGeAlD
Vandetanib—MAP2K5—parotid gland—head and neck cancer	0.000204	0.00505	CbGeAlD
Vandetanib—KDR—parotid gland—head and neck cancer	0.000204	0.00505	CbGeAlD
Vandetanib—YES1—connective tissue—head and neck cancer	0.000203	0.00502	CbGeAlD
Vandetanib—LCK—trachea—head and neck cancer	0.000202	0.00501	CbGeAlD
Vandetanib—AXL—trachea—head and neck cancer	0.000202	0.00499	CbGeAlD
Vandetanib—Dysuria—Hydroxyurea—head and neck cancer	0.000201	0.00697	CcSEcCtD
Vandetanib—Neutropenia—Hydroxyurea—head and neck cancer	0.000201	0.00697	CcSEcCtD
Vandetanib—FLT4—lymphoid tissue—head and neck cancer	0.0002	0.00494	CbGeAlD
Vandetanib—BLK—lymph node—head and neck cancer	0.000199	0.00492	CbGeAlD
Vandetanib—LTK—lymph node—head and neck cancer	0.000197	0.00487	CbGeAlD
Vandetanib—STK35—thyroid gland—head and neck cancer	0.000196	0.00484	CbGeAlD
Vandetanib—KDR—saliva-secreting gland—head and neck cancer	0.000195	0.00484	CbGeAlD
Vandetanib—MAP2K5—saliva-secreting gland—head and neck cancer	0.000195	0.00484	CbGeAlD
Vandetanib—SRC—connective tissue—head and neck cancer	0.000195	0.00483	CbGeAlD
Vandetanib—SLK—trachea—head and neck cancer	0.000194	0.0048	CbGeAlD
Vandetanib—IRAK4—lymphoid tissue—head and neck cancer	0.000194	0.0048	CbGeAlD
Vandetanib—Infestation NOS—Hydroxyurea—head and neck cancer	0.000192	0.00665	CcSEcCtD
Vandetanib—Infestation—Hydroxyurea—head and neck cancer	0.000192	0.00665	CcSEcCtD
Vandetanib—Gefitinib—CYP1A1—head and neck cancer	0.000191	0.078	CrCbGaD
Vandetanib—ABL2—thyroid gland—head and neck cancer	0.000191	0.00472	CbGeAlD
Vandetanib—ERBB3—lymphoid tissue—head and neck cancer	0.00019	0.00471	CbGeAlD
Vandetanib—Haemoglobin—Vinblastine—head and neck cancer	0.00019	0.00658	CcSEcCtD
Vandetanib—Haemorrhage—Vinblastine—head and neck cancer	0.000189	0.00654	CcSEcCtD
Vandetanib—FYN—trachea—head and neck cancer	0.000189	0.00467	CbGeAlD
Vandetanib—Blood bilirubin increased—Docetaxel—head and neck cancer	0.000188	0.00653	CcSEcCtD
Vandetanib—Dermatitis bullous—Fluorouracil—head and neck cancer	0.000187	0.00649	CcSEcCtD
Vandetanib—Stomatitis—Hydroxyurea—head and neck cancer	0.000187	0.00648	CcSEcCtD
Vandetanib—EGFR—thyroid gland—head and neck cancer	0.000186	0.00461	CbGeAlD
Vandetanib—SRC—epithelium—head and neck cancer	0.000185	0.00459	CbGeAlD
Vandetanib—MAP4K5—trachea—head and neck cancer	0.000184	0.00456	CbGeAlD
Vandetanib—Cardiac failure—Fluorouracil—head and neck cancer	0.000184	0.00636	CcSEcCtD
Vandetanib—Lethargy—Fluorouracil—head and neck cancer	0.000183	0.00633	CcSEcCtD
Vandetanib—FLT4—thyroid gland—head and neck cancer	0.000181	0.00449	CbGeAlD
Vandetanib—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000181	0.00629	CcSEcCtD
Vandetanib—Respiratory failure—Docetaxel—head and neck cancer	0.000181	0.00629	CcSEcCtD
Vandetanib—RIPK2—thyroid gland—head and neck cancer	0.00018	0.00447	CbGeAlD
Vandetanib—VEGFA—thyroid gland—head and neck cancer	0.00018	0.00445	CbGeAlD
Vandetanib—KDR—connective tissue—head and neck cancer	0.00018	0.00444	CbGeAlD
Vandetanib—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000179	0.00621	CcSEcCtD
Vandetanib—FMO1—thyroid gland—head and neck cancer	0.000179	0.00443	CbGeAlD
Vandetanib—MKNK1—lymphoid tissue—head and neck cancer	0.000179	0.00442	CbGeAlD
Vandetanib—PDGFRB—parotid gland—head and neck cancer	0.000177	0.00437	CbGeAlD
Vandetanib—FGR—lymphoid tissue—head and neck cancer	0.000176	0.00436	CbGeAlD
Vandetanib—RET—lymphoid tissue—head and neck cancer	0.000176	0.00436	CbGeAlD
Vandetanib—EPHB6—trachea—head and neck cancer	0.000176	0.00436	CbGeAlD
Vandetanib—IRAK4—thyroid gland—head and neck cancer	0.000176	0.00436	CbGeAlD
Vandetanib—AXL—lymphoid tissue—head and neck cancer	0.000176	0.00435	CbGeAlD
Vandetanib—STK35—head—head and neck cancer	0.000174	0.0043	CbGeAlD
Vandetanib—Haemoglobin—Hydroxyurea—head and neck cancer	0.000173	0.006	CcSEcCtD
Vandetanib—ERBB3—thyroid gland—head and neck cancer	0.000173	0.00427	CbGeAlD
Vandetanib—Haemorrhage—Hydroxyurea—head and neck cancer	0.000172	0.00597	CcSEcCtD
Vandetanib—Colitis—Docetaxel—head and neck cancer	0.000171	0.00593	CcSEcCtD
Vandetanib—KDR—epithelium—head and neck cancer	0.00017	0.00422	CbGeAlD
Vandetanib—YES1—trachea—head and neck cancer	0.00017	0.00422	CbGeAlD
Vandetanib—Cardiac arrest—Fluorouracil—head and neck cancer	0.00017	0.0059	CcSEcCtD
Vandetanib—PDGFRB—saliva-secreting gland—head and neck cancer	0.000169	0.00419	CbGeAlD
Vandetanib—Alopecia—Vinblastine—head and neck cancer	0.000167	0.00578	CcSEcCtD
Vandetanib—FYN—lymphoid tissue—head and neck cancer	0.000164	0.00407	CbGeAlD
Vandetanib—Dry skin—Fluorouracil—head and neck cancer	0.000164	0.00569	CcSEcCtD
Vandetanib—MKNK1—thyroid gland—head and neck cancer	0.000162	0.00401	CbGeAlD
Vandetanib—Neoplasm—Docetaxel—head and neck cancer	0.000161	0.00558	CcSEcCtD
Vandetanib—FLT4—head—head and neck cancer	0.000161	0.00398	CbGeAlD
Vandetanib—MAP4K5—lymphoid tissue—head and neck cancer	0.000161	0.00398	CbGeAlD
Vandetanib—TEK—lymphoid tissue—head and neck cancer	0.000161	0.00398	CbGeAlD
Vandetanib—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00016	0.00555	CcSEcCtD
Vandetanib—FGR—thyroid gland—head and neck cancer	0.00016	0.00396	CbGeAlD
Vandetanib—RET—thyroid gland—head and neck cancer	0.00016	0.00396	CbGeAlD
Vandetanib—LCK—thyroid gland—head and neck cancer	0.00016	0.00396	CbGeAlD
Vandetanib—RIPK2—head—head and neck cancer	0.00016	0.00396	CbGeAlD
Vandetanib—AXL—thyroid gland—head and neck cancer	0.00016	0.00395	CbGeAlD
Vandetanib—FMO1—head—head and neck cancer	0.000159	0.00393	CbGeAlD
Vandetanib—ABL1—parotid gland—head and neck cancer	0.000157	0.0039	CbGeAlD
Vandetanib—IRAK4—head—head and neck cancer	0.000156	0.00387	CbGeAlD
Vandetanib—Angiopathy—Hydroxyurea—head and neck cancer	0.000156	0.00541	CcSEcCtD
Vandetanib—PDGFRB—connective tissue—head and neck cancer	0.000155	0.00385	CbGeAlD
Vandetanib—PLK4—lymph node—head and neck cancer	0.000155	0.00384	CbGeAlD
Vandetanib—Dysphagia—Fluorouracil—head and neck cancer	0.000155	0.00536	CcSEcCtD
Vandetanib—FMO3—thyroid gland—head and neck cancer	0.000155	0.00383	CbGeAlD
Vandetanib—Sepsis—Docetaxel—head and neck cancer	0.000155	0.00536	CcSEcCtD
Vandetanib—SLK—thyroid gland—head and neck cancer	0.000154	0.0038	CbGeAlD
Vandetanib—ERBB3—head—head and neck cancer	0.000153	0.00379	CbGeAlD
Vandetanib—Alopecia—Hydroxyurea—head and neck cancer	0.000152	0.00527	CcSEcCtD
Vandetanib—ABL1—saliva-secreting gland—head and neck cancer	0.000151	0.00373	CbGeAlD
Vandetanib—KDR—trachea—head and neck cancer	0.000151	0.00373	CbGeAlD
Vandetanib—MAP2K5—trachea—head and neck cancer	0.000151	0.00373	CbGeAlD
Vandetanib—FYN—thyroid gland—head and neck cancer	0.000149	0.00369	CbGeAlD
Vandetanib—YES1—lymphoid tissue—head and neck cancer	0.000148	0.00367	CbGeAlD
Vandetanib—PDGFRB—epithelium—head and neck cancer	0.000148	0.00365	CbGeAlD
Vandetanib—STK10—lymphoid tissue—head and neck cancer	0.000147	0.00364	CbGeAlD
Vandetanib—TEK—thyroid gland—head and neck cancer	0.000146	0.00361	CbGeAlD
Vandetanib—MAP4K5—thyroid gland—head and neck cancer	0.000146	0.00361	CbGeAlD
Vandetanib—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000144	0.00499	CcSEcCtD
Vandetanib—MKNK1—head—head and neck cancer	0.000144	0.00356	CbGeAlD
Vandetanib—BMPR1B—lymph node—head and neck cancer	0.000143	0.00354	CbGeAlD
Vandetanib—SRC—lymphoid tissue—head and neck cancer	0.000143	0.00353	CbGeAlD
Vandetanib—Convulsion—Vinblastine—head and neck cancer	0.000142	0.00493	CcSEcCtD
Vandetanib—FGR—head—head and neck cancer	0.000142	0.00352	CbGeAlD
Vandetanib—RET—head—head and neck cancer	0.000142	0.00352	CbGeAlD
Vandetanib—Hypertension—Vinblastine—head and neck cancer	0.000142	0.00492	CcSEcCtD
Vandetanib—AXL—head—head and neck cancer	0.000142	0.0035	CbGeAlD
Vandetanib—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000141	0.0049	CcSEcCtD
Vandetanib—EPHB6—thyroid gland—head and neck cancer	0.000139	0.00345	CbGeAlD
Vandetanib—Pneumonia—Fluorouracil—head and neck cancer	0.000139	0.00481	CcSEcCtD
Vandetanib—ABL1—connective tissue—head and neck cancer	0.000138	0.00343	CbGeAlD
Vandetanib—Infestation NOS—Fluorouracil—head and neck cancer	0.000138	0.00478	CcSEcCtD
Vandetanib—Infestation—Fluorouracil—head and neck cancer	0.000138	0.00478	CcSEcCtD
Vandetanib—FMO3—head—head and neck cancer	0.000137	0.0034	CbGeAlD
Vandetanib—Atrial fibrillation—Docetaxel—head and neck cancer	0.000136	0.00473	CcSEcCtD
Vandetanib—Dermatitis bullous—Docetaxel—head and neck cancer	0.000135	0.00469	CcSEcCtD
Vandetanib—YES1—thyroid gland—head and neck cancer	0.000135	0.00333	CbGeAlD
Vandetanib—Stomatitis—Fluorouracil—head and neck cancer	0.000135	0.00466	CcSEcCtD
Vandetanib—Conjunctivitis—Fluorouracil—head and neck cancer	0.000134	0.00465	CcSEcCtD
Vandetanib—Urinary tract infection—Fluorouracil—head and neck cancer	0.000134	0.00465	CcSEcCtD
Vandetanib—STK10—thyroid gland—head and neck cancer	0.000134	0.0033	CbGeAlD
Vandetanib—Cardiac failure—Docetaxel—head and neck cancer	0.000132	0.00459	CcSEcCtD
Vandetanib—FYN—head—head and neck cancer	0.000132	0.00328	CbGeAlD
Vandetanib—Lethargy—Docetaxel—head and neck cancer	0.000132	0.00457	CcSEcCtD
Vandetanib—Thrombocytopenia—Vinblastine—head and neck cancer	0.000131	0.00455	CcSEcCtD
Vandetanib—KDR—lymphoid tissue—head and neck cancer	0.000131	0.00325	CbGeAlD
Vandetanib—PDGFRB—trachea—head and neck cancer	0.00013	0.00323	CbGeAlD
Vandetanib—Epistaxis—Fluorouracil—head and neck cancer	0.00013	0.00451	CcSEcCtD
Vandetanib—Convulsion—Hydroxyurea—head and neck cancer	0.00013	0.0045	CcSEcCtD
Vandetanib—Hyponatraemia—Docetaxel—head and neck cancer	0.00013	0.0045	CcSEcCtD
Vandetanib—SRC—thyroid gland—head and neck cancer	0.00013	0.00321	CbGeAlD
Vandetanib—Sinusitis—Fluorouracil—head and neck cancer	0.000129	0.00449	CcSEcCtD
Vandetanib—TEK—head—head and neck cancer	0.000129	0.0032	CbGeAlD
Vandetanib—MAP4K5—head—head and neck cancer	0.000129	0.0032	CbGeAlD
Vandetanib—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000129	0.00448	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000127	0.00439	CcSEcCtD
Vandetanib—Haemoglobin—Fluorouracil—head and neck cancer	0.000125	0.00432	CcSEcCtD
Vandetanib—FLT3—lymph node—head and neck cancer	0.000124	0.00307	CbGeAlD
Vandetanib—Haemorrhage—Fluorouracil—head and neck cancer	0.000124	0.00429	CcSEcCtD
Vandetanib—EPHB6—head—head and neck cancer	0.000124	0.00306	CbGeAlD
Vandetanib—Oedema—Hydroxyurea—head and neck cancer	0.000122	0.00424	CcSEcCtD
Vandetanib—STK35—lymph node—head and neck cancer	0.000122	0.00301	CbGeAlD
Vandetanib—Infection—Hydroxyurea—head and neck cancer	0.000121	0.00421	CcSEcCtD
Vandetanib—Paraesthesia—Vinblastine—head and neck cancer	0.00012	0.00417	CcSEcCtD
Vandetanib—Dehydration—Docetaxel—head and neck cancer	0.00012	0.00417	CcSEcCtD
Vandetanib—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00012	0.00416	CcSEcCtD
Vandetanib—ABCC1—parotid gland—head and neck cancer	0.00012	0.00297	CbGeAlD
Vandetanib—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00012	0.00415	CcSEcCtD
Vandetanib—YES1—head—head and neck cancer	0.00012	0.00296	CbGeAlD
Vandetanib—MAP2K5—thyroid gland—head and neck cancer	0.000119	0.00295	CbGeAlD
Vandetanib—KDR—thyroid gland—head and neck cancer	0.000119	0.00295	CbGeAlD
Vandetanib—Skin disorder—Hydroxyurea—head and neck cancer	0.000119	0.00412	CcSEcCtD
Vandetanib—Dry skin—Docetaxel—head and neck cancer	0.000118	0.00411	CcSEcCtD
Vandetanib—ABL2—lymph node—head and neck cancer	0.000118	0.00293	CbGeAlD
Vandetanib—STK10—head—head and neck cancer	0.000118	0.00293	CbGeAlD
Vandetanib—Decreased appetite—Vinblastine—head and neck cancer	0.000117	0.00404	CcSEcCtD
Vandetanib—ABL1—trachea—head and neck cancer	0.000116	0.00288	CbGeAlD
Vandetanib—EGFR—lymph node—head and neck cancer	0.000116	0.00286	CbGeAlD
Vandetanib—Nasopharyngitis—Docetaxel—head and neck cancer	0.000116	0.00401	CcSEcCtD
Vandetanib—SRC—head—head and neck cancer	0.000115	0.00285	CbGeAlD
Vandetanib—Pain—Vinblastine—head and neck cancer	0.000115	0.00397	CcSEcCtD
Vandetanib—Constipation—Vinblastine—head and neck cancer	0.000115	0.00397	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000114	0.00395	CcSEcCtD
Vandetanib—PDGFRB—lymphoid tissue—head and neck cancer	0.000114	0.00281	CbGeAlD
Vandetanib—FLT4—lymph node—head and neck cancer	0.000113	0.00279	CbGeAlD
Vandetanib—RIPK2—lymph node—head and neck cancer	0.000112	0.00277	CbGeAlD
Vandetanib—VEGFA—lymph node—head and neck cancer	0.000112	0.00277	CbGeAlD
Vandetanib—Dysphagia—Docetaxel—head and neck cancer	0.000112	0.00387	CcSEcCtD
Vandetanib—FMO1—lymph node—head and neck cancer	0.000111	0.00275	CbGeAlD
Vandetanib—Arrhythmia—Fluorouracil—head and neck cancer	0.000111	0.00384	CcSEcCtD
Vandetanib—Bronchospasm—Docetaxel—head and neck cancer	0.00011	0.00381	CcSEcCtD
Vandetanib—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00011	0.0038	CcSEcCtD
Vandetanib—Alopecia—Fluorouracil—head and neck cancer	0.000109	0.00379	CcSEcCtD
Vandetanib—IRAK4—lymph node—head and neck cancer	0.000109	0.00271	CbGeAlD
Vandetanib—Dyspnoea—Hydroxyurea—head and neck cancer	0.000109	0.00378	CcSEcCtD
Vandetanib—Dyspepsia—Hydroxyurea—head and neck cancer	0.000108	0.00373	CcSEcCtD
Vandetanib—ERBB3—lymph node—head and neck cancer	0.000107	0.00266	CbGeAlD
Vandetanib—Decreased appetite—Hydroxyurea—head and neck cancer	0.000106	0.00368	CcSEcCtD
Vandetanib—Abdominal pain—Vinblastine—head and neck cancer	0.000106	0.00367	CcSEcCtD
Vandetanib—MAP2K5—head—head and neck cancer	0.000106	0.00262	CbGeAlD
Vandetanib—KDR—head—head and neck cancer	0.000106	0.00262	CbGeAlD
Vandetanib—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000106	0.00366	CcSEcCtD
Vandetanib—Fatigue—Hydroxyurea—head and neck cancer	0.000105	0.00365	CcSEcCtD
Vandetanib—Pain—Hydroxyurea—head and neck cancer	0.000105	0.00362	CcSEcCtD
Vandetanib—Constipation—Hydroxyurea—head and neck cancer	0.000105	0.00362	CcSEcCtD
Vandetanib—Neutropenia—Docetaxel—head and neck cancer	0.000104	0.00362	CcSEcCtD
Vandetanib—PDGFRB—thyroid gland—head and neck cancer	0.000103	0.00255	CbGeAlD
Vandetanib—Vision blurred—Fluorouracil—head and neck cancer	0.000102	0.00352	CcSEcCtD
Vandetanib—ABL1—lymphoid tissue—head and neck cancer	0.000101	0.00251	CbGeAlD
Vandetanib—Weight decreased—Docetaxel—head and neck cancer	0.000101	0.0035	CcSEcCtD
Vandetanib—MKNK1—lymph node—head and neck cancer	0.000101	0.00249	CbGeAlD
Vandetanib—Pneumonia—Docetaxel—head and neck cancer	0.0001	0.00347	CcSEcCtD
Vandetanib—Infestation NOS—Docetaxel—head and neck cancer	9.96e-05	0.00345	CcSEcCtD
Vandetanib—Infestation—Docetaxel—head and neck cancer	9.96e-05	0.00345	CcSEcCtD
Vandetanib—RET—lymph node—head and neck cancer	9.95e-05	0.00246	CbGeAlD
Vandetanib—FGR—lymph node—head and neck cancer	9.95e-05	0.00246	CbGeAlD
Vandetanib—LCK—lymph node—head and neck cancer	9.95e-05	0.00246	CbGeAlD
Vandetanib—ABCG2—parotid gland—head and neck cancer	9.92e-05	0.00246	CbGeAlD
Vandetanib—AXL—lymph node—head and neck cancer	9.91e-05	0.00245	CbGeAlD
Vandetanib—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	9.88e-05	0.00342	CcSEcCtD
Vandetanib—Renal failure—Docetaxel—head and neck cancer	9.79e-05	0.00339	CcSEcCtD
Vandetanib—Stomatitis—Docetaxel—head and neck cancer	9.71e-05	0.00337	CcSEcCtD
Vandetanib—Conjunctivitis—Docetaxel—head and neck cancer	9.68e-05	0.00336	CcSEcCtD
Vandetanib—Body temperature increased—Hydroxyurea—head and neck cancer	9.67e-05	0.00335	CcSEcCtD
Vandetanib—Asthenia—Vinblastine—head and neck cancer	9.62e-05	0.00333	CcSEcCtD
Vandetanib—FMO3—lymph node—head and neck cancer	9.61e-05	0.00238	CbGeAlD
Vandetanib—SLK—lymph node—head and neck cancer	9.54e-05	0.00236	CbGeAlD
Vandetanib—ABCG2—saliva-secreting gland—head and neck cancer	9.5e-05	0.00235	CbGeAlD
Vandetanib—Hepatobiliary disease—Docetaxel—head and neck cancer	9.42e-05	0.00327	CcSEcCtD
Vandetanib—Epistaxis—Docetaxel—head and neck cancer	9.4e-05	0.00326	CcSEcCtD
Vandetanib—Convulsion—Fluorouracil—head and neck cancer	9.35e-05	0.00324	CcSEcCtD
Vandetanib—FYN—lymph node—head and neck cancer	9.27e-05	0.0023	CbGeAlD
Vandetanib—ABL1—thyroid gland—head and neck cancer	9.2e-05	0.00228	CbGeAlD
Vandetanib—Chest pain—Fluorouracil—head and neck cancer	9.18e-05	0.00318	CcSEcCtD
Vandetanib—Diarrhoea—Vinblastine—head and neck cancer	9.18e-05	0.00318	CcSEcCtD
Vandetanib—PDGFRB—head—head and neck cancer	9.16e-05	0.00227	CbGeAlD
Vandetanib—TEK—lymph node—head and neck cancer	9.06e-05	0.00224	CbGeAlD
Vandetanib—MAP4K5—lymph node—head and neck cancer	9.06e-05	0.00224	CbGeAlD
Vandetanib—Haemoglobin—Docetaxel—head and neck cancer	8.99e-05	0.00312	CcSEcCtD
Vandetanib—Haemorrhage—Docetaxel—head and neck cancer	8.94e-05	0.0031	CcSEcCtD
Vandetanib—Dizziness—Vinblastine—head and neck cancer	8.87e-05	0.00307	CcSEcCtD
Vandetanib—ABCC1—trachea—head and neck cancer	8.86e-05	0.00219	CbGeAlD
Vandetanib—Urinary tract disorder—Docetaxel—head and neck cancer	8.83e-05	0.00306	CcSEcCtD
Vandetanib—Oedema—Fluorouracil—head and neck cancer	8.8e-05	0.00305	CcSEcCtD
Vandetanib—Asthenia—Hydroxyurea—head and neck cancer	8.77e-05	0.00304	CcSEcCtD
Vandetanib—Urethral disorder—Docetaxel—head and neck cancer	8.77e-05	0.00304	CcSEcCtD
Vandetanib—Infection—Fluorouracil—head and neck cancer	8.75e-05	0.00303	CcSEcCtD
Vandetanib—EPHB6—lymph node—head and neck cancer	8.66e-05	0.00214	CbGeAlD
Vandetanib—Nervous system disorder—Fluorouracil—head and neck cancer	8.63e-05	0.00299	CcSEcCtD
Vandetanib—Thrombocytopenia—Fluorouracil—head and neck cancer	8.62e-05	0.00299	CcSEcCtD
Vandetanib—Visual impairment—Docetaxel—head and neck cancer	8.62e-05	0.00299	CcSEcCtD
Vandetanib—Vomiting—Vinblastine—head and neck cancer	8.53e-05	0.00296	CcSEcCtD
Vandetanib—Erythema multiforme—Docetaxel—head and neck cancer	8.46e-05	0.00293	CcSEcCtD
Vandetanib—Headache—Vinblastine—head and neck cancer	8.4e-05	0.00291	CcSEcCtD
Vandetanib—YES1—lymph node—head and neck cancer	8.37e-05	0.00207	CbGeAlD
Vandetanib—Diarrhoea—Hydroxyurea—head and neck cancer	8.37e-05	0.0029	CcSEcCtD
Vandetanib—Eye disorder—Docetaxel—head and neck cancer	8.36e-05	0.0029	CcSEcCtD
Vandetanib—Cardiac disorder—Docetaxel—head and neck cancer	8.3e-05	0.00288	CcSEcCtD
Vandetanib—STK10—lymph node—head and neck cancer	8.29e-05	0.00205	CbGeAlD
Vandetanib—ABL1—head—head and neck cancer	8.16e-05	0.00202	CbGeAlD
Vandetanib—Angiopathy—Docetaxel—head and neck cancer	8.11e-05	0.00281	CcSEcCtD
Vandetanib—Dizziness—Hydroxyurea—head and neck cancer	8.09e-05	0.0028	CcSEcCtD
Vandetanib—Mediastinal disorder—Docetaxel—head and neck cancer	8.06e-05	0.00279	CcSEcCtD
Vandetanib—SRC—lymph node—head and neck cancer	8.05e-05	0.00199	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	8.02e-05	0.00278	CcSEcCtD
Vandetanib—Arrhythmia—Docetaxel—head and neck cancer	7.99e-05	0.00277	CcSEcCtD
Vandetanib—Nausea—Vinblastine—head and neck cancer	7.97e-05	0.00276	CcSEcCtD
Vandetanib—Insomnia—Fluorouracil—head and neck cancer	7.96e-05	0.00276	CcSEcCtD
Vandetanib—Paraesthesia—Fluorouracil—head and neck cancer	7.9e-05	0.00274	CcSEcCtD
Vandetanib—Alopecia—Docetaxel—head and neck cancer	7.9e-05	0.00274	CcSEcCtD
Vandetanib—Dyspnoea—Fluorouracil—head and neck cancer	7.85e-05	0.00272	CcSEcCtD
Vandetanib—Mental disorder—Docetaxel—head and neck cancer	7.83e-05	0.00272	CcSEcCtD
Vandetanib—Malnutrition—Docetaxel—head and neck cancer	7.78e-05	0.0027	CcSEcCtD
Vandetanib—Vomiting—Hydroxyurea—head and neck cancer	7.78e-05	0.00269	CcSEcCtD
Vandetanib—Dyspepsia—Fluorouracil—head and neck cancer	7.75e-05	0.00269	CcSEcCtD
Vandetanib—Rash—Hydroxyurea—head and neck cancer	7.71e-05	0.00267	CcSEcCtD
Vandetanib—Dermatitis—Hydroxyurea—head and neck cancer	7.7e-05	0.00267	CcSEcCtD
Vandetanib—Headache—Hydroxyurea—head and neck cancer	7.66e-05	0.00266	CcSEcCtD
Vandetanib—Decreased appetite—Fluorouracil—head and neck cancer	7.65e-05	0.00265	CcSEcCtD
Vandetanib—Dysgeusia—Docetaxel—head and neck cancer	7.62e-05	0.00264	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Fluorouracil—head and neck cancer	7.6e-05	0.00263	CcSEcCtD
Vandetanib—Pain—Fluorouracil—head and neck cancer	7.53e-05	0.00261	CcSEcCtD
Vandetanib—Muscle spasms—Docetaxel—head and neck cancer	7.48e-05	0.00259	CcSEcCtD
Vandetanib—MAP2K5—lymph node—head and neck cancer	7.41e-05	0.00183	CbGeAlD
Vandetanib—KDR—lymph node—head and neck cancer	7.41e-05	0.00183	CbGeAlD
Vandetanib—Nausea—Hydroxyurea—head and neck cancer	7.26e-05	0.00252	CcSEcCtD
Vandetanib—ABCC1—thyroid gland—head and neck cancer	7.01e-05	0.00173	CbGeAlD
Vandetanib—Body temperature increased—Fluorouracil—head and neck cancer	6.96e-05	0.00241	CcSEcCtD
Vandetanib—Loss of consciousness—Docetaxel—head and neck cancer	6.84e-05	0.00237	CcSEcCtD
Vandetanib—Cough—Docetaxel—head and neck cancer	6.79e-05	0.00235	CcSEcCtD
Vandetanib—Convulsion—Docetaxel—head and neck cancer	6.75e-05	0.00234	CcSEcCtD
Vandetanib—Hypertension—Docetaxel—head and neck cancer	6.72e-05	0.00233	CcSEcCtD
Vandetanib—Arthralgia—Docetaxel—head and neck cancer	6.63e-05	0.0023	CcSEcCtD
Vandetanib—Chest pain—Docetaxel—head and neck cancer	6.63e-05	0.0023	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	6.58e-05	0.00228	CcSEcCtD
Vandetanib—Dry mouth—Docetaxel—head and neck cancer	6.48e-05	0.00225	CcSEcCtD
Vandetanib—PDGFRB—lymph node—head and neck cancer	6.41e-05	0.00159	CbGeAlD
Vandetanib—Oedema—Docetaxel—head and neck cancer	6.35e-05	0.0022	CcSEcCtD
Vandetanib—Infection—Docetaxel—head and neck cancer	6.31e-05	0.00219	CcSEcCtD
Vandetanib—Nervous system disorder—Docetaxel—head and neck cancer	6.23e-05	0.00216	CcSEcCtD
Vandetanib—Pruritus—Fluorouracil—head and neck cancer	6.23e-05	0.00216	CcSEcCtD
Vandetanib—Thrombocytopenia—Docetaxel—head and neck cancer	6.22e-05	0.00216	CcSEcCtD
Vandetanib—Skin disorder—Docetaxel—head and neck cancer	6.17e-05	0.00214	CcSEcCtD
Vandetanib—Diarrhoea—Fluorouracil—head and neck cancer	6.02e-05	0.00209	CcSEcCtD
Vandetanib—ORM1—lymph node—head and neck cancer	6.01e-05	0.00149	CbGeAlD
Vandetanib—Dizziness—Fluorouracil—head and neck cancer	5.82e-05	0.00202	CcSEcCtD
Vandetanib—ABCG2—thyroid gland—head and neck cancer	5.8e-05	0.00144	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Docetaxel—head and neck cancer	5.79e-05	0.00201	CcSEcCtD
Vandetanib—Insomnia—Docetaxel—head and neck cancer	5.75e-05	0.00199	CcSEcCtD
Vandetanib—ABL1—lymph node—head and neck cancer	5.71e-05	0.00141	CbGeAlD
Vandetanib—Paraesthesia—Docetaxel—head and neck cancer	5.71e-05	0.00198	CcSEcCtD
Vandetanib—Dyspnoea—Docetaxel—head and neck cancer	5.66e-05	0.00196	CcSEcCtD
Vandetanib—Vomiting—Fluorouracil—head and neck cancer	5.6e-05	0.00194	CcSEcCtD
Vandetanib—Dyspepsia—Docetaxel—head and neck cancer	5.59e-05	0.00194	CcSEcCtD
Vandetanib—Rash—Fluorouracil—head and neck cancer	5.55e-05	0.00192	CcSEcCtD
Vandetanib—Dermatitis—Fluorouracil—head and neck cancer	5.55e-05	0.00192	CcSEcCtD
Vandetanib—Decreased appetite—Docetaxel—head and neck cancer	5.52e-05	0.00191	CcSEcCtD
Vandetanib—Headache—Fluorouracil—head and neck cancer	5.51e-05	0.00191	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Docetaxel—head and neck cancer	5.49e-05	0.0019	CcSEcCtD
Vandetanib—Fatigue—Docetaxel—head and neck cancer	5.48e-05	0.0019	CcSEcCtD
Vandetanib—Pain—Docetaxel—head and neck cancer	5.43e-05	0.00188	CcSEcCtD
Vandetanib—Constipation—Docetaxel—head and neck cancer	5.43e-05	0.00188	CcSEcCtD
Vandetanib—ALB—lymph node—head and neck cancer	5.27e-05	0.00131	CbGeAlD
Vandetanib—Nausea—Fluorouracil—head and neck cancer	5.23e-05	0.00181	CcSEcCtD
Vandetanib—Gastrointestinal pain—Docetaxel—head and neck cancer	5.2e-05	0.0018	CcSEcCtD
Vandetanib—Body temperature increased—Docetaxel—head and neck cancer	5.02e-05	0.00174	CcSEcCtD
Vandetanib—Abdominal pain—Docetaxel—head and neck cancer	5.02e-05	0.00174	CcSEcCtD
Vandetanib—Asthenia—Docetaxel—head and neck cancer	4.56e-05	0.00158	CcSEcCtD
Vandetanib—Pruritus—Docetaxel—head and neck cancer	4.5e-05	0.00156	CcSEcCtD
Vandetanib—ABCC1—lymph node—head and neck cancer	4.35e-05	0.00108	CbGeAlD
Vandetanib—Diarrhoea—Docetaxel—head and neck cancer	4.35e-05	0.00151	CcSEcCtD
Vandetanib—Dizziness—Docetaxel—head and neck cancer	4.2e-05	0.00146	CcSEcCtD
Vandetanib—Vomiting—Docetaxel—head and neck cancer	4.04e-05	0.0014	CcSEcCtD
Vandetanib—Rash—Docetaxel—head and neck cancer	4.01e-05	0.00139	CcSEcCtD
Vandetanib—Dermatitis—Docetaxel—head and neck cancer	4e-05	0.00139	CcSEcCtD
Vandetanib—Headache—Docetaxel—head and neck cancer	3.98e-05	0.00138	CcSEcCtD
Vandetanib—Nausea—Docetaxel—head and neck cancer	3.77e-05	0.00131	CcSEcCtD
Vandetanib—ABCG2—lymph node—head and neck cancer	3.6e-05	0.000892	CbGeAlD
Vandetanib—FYN—Immune System—MAPK3—head and neck cancer	1.98e-06	2.73e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTEN—head and neck cancer	1.96e-06	2.71e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MAPK1—head and neck cancer	1.96e-06	2.71e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EGFR—head and neck cancer	1.96e-06	2.71e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—MAPK1—head and neck cancer	1.95e-06	2.7e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—EGFR—head and neck cancer	1.95e-06	2.7e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—PTEN—head and neck cancer	1.93e-06	2.66e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NOTCH1—head and neck cancer	1.92e-06	2.66e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HRAS—head and neck cancer	1.91e-06	2.64e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—MAPK1—head and neck cancer	1.91e-06	2.64e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—AKT1—head and neck cancer	1.91e-06	2.64e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—AKT1—head and neck cancer	1.91e-06	2.64e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—STAT3—head and neck cancer	1.91e-06	2.64e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—EGFR—head and neck cancer	1.91e-06	2.64e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MAPK1—head and neck cancer	1.91e-06	2.64e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EGFR—head and neck cancer	1.91e-06	2.64e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—AKT1—head and neck cancer	1.91e-06	2.63e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—MAPK1—head and neck cancer	1.9e-06	2.63e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EGFR—head and neck cancer	1.9e-06	2.63e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—AKT1—head and neck cancer	1.9e-06	2.63e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MAPK3—head and neck cancer	1.89e-06	2.62e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MAPK1—head and neck cancer	1.89e-06	2.61e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EGFR—head and neck cancer	1.89e-06	2.61e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—STAT3—head and neck cancer	1.89e-06	2.61e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—MAPK1—head and neck cancer	1.88e-06	2.6e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—EGFR—head and neck cancer	1.88e-06	2.6e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—head and neck cancer	1.88e-06	2.6e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—MAPK3—head and neck cancer	1.88e-06	2.59e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—AKT1—head and neck cancer	1.87e-06	2.59e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—MAPK3—head and neck cancer	1.87e-06	2.58e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—PIK3CA—head and neck cancer	1.86e-06	2.57e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTEN—head and neck cancer	1.84e-06	2.55e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—VEGFA—head and neck cancer	1.84e-06	2.54e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HRAS—head and neck cancer	1.83e-06	2.54e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—TYMS—head and neck cancer	1.83e-06	2.53e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—AKT1—head and neck cancer	1.83e-06	2.53e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MAPK3—head and neck cancer	1.82e-06	2.52e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—STAT3—head and neck cancer	1.82e-06	2.52e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—AKT1—head and neck cancer	1.82e-06	2.51e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL2—head and neck cancer	1.81e-06	2.5e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GSTM1—head and neck cancer	1.81e-06	2.5e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—head and neck cancer	1.8e-06	2.5e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MAPK3—head and neck cancer	1.8e-06	2.49e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MAPK1—head and neck cancer	1.8e-06	2.49e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EGFR—head and neck cancer	1.8e-06	2.49e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—head and neck cancer	1.8e-06	2.48e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—STAT3—head and neck cancer	1.79e-06	2.47e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—MAPK1—head and neck cancer	1.78e-06	2.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—MAPK1—head and neck cancer	1.78e-06	2.46e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTEN—head and neck cancer	1.78e-06	2.46e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—STAT3—head and neck cancer	1.75e-06	2.42e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MAPK3—head and neck cancer	1.74e-06	2.41e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MAPK1—head and neck cancer	1.74e-06	2.4e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—EGFR—head and neck cancer	1.74e-06	2.4e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—DPYD—head and neck cancer	1.73e-06	2.4e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GPX1—head and neck cancer	1.73e-06	2.4e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—STAT3—head and neck cancer	1.72e-06	2.38e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HRAS—head and neck cancer	1.72e-06	2.38e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CYP1A1—head and neck cancer	1.72e-06	2.37e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MAPK1—head and neck cancer	1.71e-06	2.37e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EGFR—head and neck cancer	1.71e-06	2.37e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MAPK3—head and neck cancer	1.71e-06	2.36e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—PTEN—head and neck cancer	1.7e-06	2.36e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOTCH1—head and neck cancer	1.7e-06	2.35e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—PIK3CA—head and neck cancer	1.7e-06	2.35e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—PIK3CA—head and neck cancer	1.69e-06	2.34e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—head and neck cancer	1.69e-06	2.33e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MAPK3—head and neck cancer	1.67e-06	2.31e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—PIK3CA—head and neck cancer	1.66e-06	2.29e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MAPK1—head and neck cancer	1.66e-06	2.29e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EGFR—head and neck cancer	1.66e-06	2.29e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PIK3CA—head and neck cancer	1.66e-06	2.29e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—head and neck cancer	1.65e-06	2.29e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—STAT3—head and neck cancer	1.65e-06	2.28e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—PIK3CA—head and neck cancer	1.65e-06	2.28e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL2—head and neck cancer	1.65e-06	2.28e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—YAP1—head and neck cancer	1.65e-06	2.28e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—MAPK3—head and neck cancer	1.65e-06	2.27e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—head and neck cancer	1.64e-06	2.27e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTEN—head and neck cancer	1.64e-06	2.27e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PIK3CA—head and neck cancer	1.64e-06	2.26e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—PIK3CA—head and neck cancer	1.63e-06	2.26e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MAPK1—head and neck cancer	1.62e-06	2.25e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—head and neck cancer	1.62e-06	2.24e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL2—head and neck cancer	1.61e-06	2.23e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCND1—head and neck cancer	1.61e-06	2.22e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—head and neck cancer	1.6e-06	2.21e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MAPK1—head and neck cancer	1.59e-06	2.2e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EGFR—head and neck cancer	1.59e-06	2.2e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—STAT3—head and neck cancer	1.59e-06	2.2e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL2—head and neck cancer	1.59e-06	2.2e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—head and neck cancer	1.58e-06	2.19e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MAPK3—head and neck cancer	1.58e-06	2.18e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTEN—head and neck cancer	1.57e-06	2.18e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCND1—head and neck cancer	1.57e-06	2.18e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—head and neck cancer	1.57e-06	2.17e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—head and neck cancer	1.57e-06	2.17e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—MAPK1—head and neck cancer	1.57e-06	2.16e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—head and neck cancer	1.57e-06	2.16e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PIK3CA—head and neck cancer	1.56e-06	2.16e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PTEN—head and neck cancer	1.55e-06	2.14e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—head and neck cancer	1.55e-06	2.14e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PIK3CA—head and neck cancer	1.55e-06	2.14e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—PIK3CA—head and neck cancer	1.54e-06	2.13e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—head and neck cancer	1.53e-06	2.12e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—head and neck cancer	1.53e-06	2.12e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—head and neck cancer	1.53e-06	2.11e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—STAT3—head and neck cancer	1.52e-06	2.11e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MAPK3—head and neck cancer	1.52e-06	2.1e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTEN—head and neck cancer	1.52e-06	2.1e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—head and neck cancer	1.52e-06	2.1e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—head and neck cancer	1.51e-06	2.09e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—head and neck cancer	1.51e-06	2.09e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—head and neck cancer	1.51e-06	2.08e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MAPK1—head and neck cancer	1.5e-06	2.07e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—head and neck cancer	1.5e-06	2.07e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTEN—head and neck cancer	1.5e-06	2.07e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—head and neck cancer	1.49e-06	2.06e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK3—head and neck cancer	1.46e-06	2.01e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—head and neck cancer	1.45e-06	2e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MAPK1—head and neck cancer	1.45e-06	2e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—head and neck cancer	1.45e-06	2e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTEN—head and neck cancer	1.44e-06	1.99e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—head and neck cancer	1.44e-06	1.99e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—head and neck cancer	1.44e-06	1.99e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—head and neck cancer	1.43e-06	1.98e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—head and neck cancer	1.43e-06	1.97e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.41e-06	1.95e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—head and neck cancer	1.41e-06	1.95e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—head and neck cancer	1.41e-06	1.95e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—head and neck cancer	1.4e-06	1.94e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—head and neck cancer	1.39e-06	1.93e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—head and neck cancer	1.39e-06	1.92e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—head and neck cancer	1.39e-06	1.92e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—head and neck cancer	1.39e-06	1.92e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK1—head and neck cancer	1.39e-06	1.92e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—head and neck cancer	1.39e-06	1.92e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—head and neck cancer	1.38e-06	1.91e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—head and neck cancer	1.38e-06	1.91e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—head and neck cancer	1.38e-06	1.9e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—head and neck cancer	1.37e-06	1.9e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—head and neck cancer	1.37e-06	1.9e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—head and neck cancer	1.36e-06	1.88e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—head and neck cancer	1.36e-06	1.88e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—head and neck cancer	1.35e-06	1.87e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—head and neck cancer	1.35e-06	1.87e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—head and neck cancer	1.35e-06	1.87e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—head and neck cancer	1.35e-06	1.86e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK3—head and neck cancer	1.34e-06	1.86e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—head and neck cancer	1.34e-06	1.85e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—head and neck cancer	1.34e-06	1.85e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—head and neck cancer	1.34e-06	1.85e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—head and neck cancer	1.33e-06	1.84e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—head and neck cancer	1.33e-06	1.84e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK3—head and neck cancer	1.33e-06	1.83e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—head and neck cancer	1.32e-06	1.83e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—head and neck cancer	1.3e-06	1.8e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—head and neck cancer	1.3e-06	1.8e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK3—head and neck cancer	1.3e-06	1.79e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTEN—head and neck cancer	1.29e-06	1.79e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—head and neck cancer	1.29e-06	1.78e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK1—head and neck cancer	1.28e-06	1.77e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—head and neck cancer	1.28e-06	1.77e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK3—head and neck cancer	1.28e-06	1.77e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—head and neck cancer	1.28e-06	1.77e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—head and neck cancer	1.28e-06	1.77e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—head and neck cancer	1.27e-06	1.75e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK1—head and neck cancer	1.26e-06	1.74e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—head and neck cancer	1.26e-06	1.74e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—head and neck cancer	1.26e-06	1.74e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—head and neck cancer	1.26e-06	1.74e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—head and neck cancer	1.25e-06	1.73e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTEN—head and neck cancer	1.24e-06	1.72e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK1—head and neck cancer	1.23e-06	1.71e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—head and neck cancer	1.23e-06	1.71e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—head and neck cancer	1.23e-06	1.7e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK1—head and neck cancer	1.22e-06	1.68e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—head and neck cancer	1.22e-06	1.68e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—head and neck cancer	1.22e-06	1.68e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—head and neck cancer	1.2e-06	1.66e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—head and neck cancer	1.2e-06	1.66e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—head and neck cancer	1.17e-06	1.62e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—head and neck cancer	1.17e-06	1.62e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—head and neck cancer	1.17e-06	1.61e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—head and neck cancer	1.16e-06	1.6e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—head and neck cancer	1.16e-06	1.6e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—head and neck cancer	1.16e-06	1.6e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—head and neck cancer	1.15e-06	1.59e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—head and neck cancer	1.14e-06	1.58e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—head and neck cancer	1.13e-06	1.56e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—head and neck cancer	1.12e-06	1.55e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—head and neck cancer	1.11e-06	1.54e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—head and neck cancer	1.11e-06	1.54e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—head and neck cancer	1.11e-06	1.54e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—head and neck cancer	1.11e-06	1.53e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK3—head and neck cancer	1.1e-06	1.53e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTEN—head and neck cancer	1.1e-06	1.52e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—head and neck cancer	1.09e-06	1.51e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—head and neck cancer	1.07e-06	1.48e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK3—head and neck cancer	1.06e-06	1.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—head and neck cancer	1.06e-06	1.47e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—head and neck cancer	1.06e-06	1.46e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—head and neck cancer	1.05e-06	1.46e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK1—head and neck cancer	1.05e-06	1.45e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—head and neck cancer	1.04e-06	1.43e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—head and neck cancer	1.03e-06	1.42e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—head and neck cancer	1.02e-06	1.42e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—head and neck cancer	1.02e-06	1.41e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—head and neck cancer	1.02e-06	1.41e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—head and neck cancer	1.02e-06	1.41e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—head and neck cancer	1.01e-06	1.4e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK1—head and neck cancer	1.01e-06	1.4e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—head and neck cancer	1.01e-06	1.4e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—head and neck cancer	9.95e-07	1.38e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—head and neck cancer	9.91e-07	1.37e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TYMS—head and neck cancer	9.89e-07	1.37e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—head and neck cancer	9.86e-07	1.36e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—head and neck cancer	9.82e-07	1.36e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTM1—head and neck cancer	9.77e-07	1.35e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—head and neck cancer	9.76e-07	1.35e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—head and neck cancer	9.45e-07	1.31e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK3—head and neck cancer	9.42e-07	1.3e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GPX1—head and neck cancer	9.36e-07	1.29e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP1A1—head and neck cancer	9.26e-07	1.28e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—head and neck cancer	9.11e-07	1.26e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—head and neck cancer	9.07e-07	1.25e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK1—head and neck cancer	8.96e-07	1.24e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—head and neck cancer	8.96e-07	1.24e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—head and neck cancer	8.94e-07	1.24e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTEN—head and neck cancer	8.9e-07	1.23e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—head and neck cancer	8.82e-07	1.22e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—head and neck cancer	8.78e-07	1.21e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—head and neck cancer	8.75e-07	1.21e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—head and neck cancer	8.62e-07	1.19e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—head and neck cancer	8.5e-07	1.17e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—head and neck cancer	8.43e-07	1.17e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—head and neck cancer	8.31e-07	1.15e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—head and neck cancer	8.13e-07	1.12e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—head and neck cancer	7.77e-07	1.08e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—head and neck cancer	7.52e-07	1.04e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—head and neck cancer	7.44e-07	1.03e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—head and neck cancer	7.19e-07	9.95e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—head and neck cancer	7.17e-07	9.92e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—head and neck cancer	6.35e-07	8.78e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—head and neck cancer	6.28e-07	8.68e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—head and neck cancer	5.51e-07	7.62e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—head and neck cancer	5.13e-07	7.09e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTEN—head and neck cancer	4.8e-07	6.64e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—head and neck cancer	3.39e-07	4.69e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—head and neck cancer	2.77e-07	3.83e-06	CbGpPWpGaD
